Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant fowlpox-GM-CSF
- Development stage
- Phase 1
- Lead developer
- National Cancer Institute
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intravesical, Intratumoral
01
Overview
A cancer immunotherapy agent consisting of a recombinant fowlpox virus engineered to express human granulocyte-macrophage colony-stimulating factor (GM-CSF). The drug is designed as a vaccine adjuvant to enhance anti-tumor immune responses by recruiting and activating antigen-presenting dendritic cells in the tumor microenvironment, thereby promoting stronger antigen presentation and T-cell mediated immunity. It was primarily developed for use in various cancers, including bladder cancer, breast cancer, hepatocellular carcinoma, rectal adenocarcinoma, recurrent gastric cancer, salivary gland cancers, stage III colon cancer, medullary thyroid cancer, metastatic neoplasms and mammary Paget's disease. The developer is the National Cancer Institute. Clinical development reached Phase 1 but has since been discontinued[1][2][3][6].
- Other names
- recombinant fowlpox gm-csf vaccine adjuvantrFGM-CSF
02
Targets
CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)
Beyond the preview
Go deeper on recombinant fowlpox-GM-CSF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant fowlpox-GM-CSF.